Ionis Pharmaceuticals IONS Current Equity Amortized Cost
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's current equity amortized cost.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Ionis Pharmaceuticals's current equity amortized cost?
- Ionis Pharmaceuticals (IONS) reported current equity amortized cost of $21.9M in Q1 2026.
- How has Ionis Pharmaceuticals's current equity amortized cost changed year-over-year?
- Ionis Pharmaceuticals's current equity amortized cost decreased by 37.5% year-over-year, from $35.01M to $21.9M.
- What is the long-term trend for Ionis Pharmaceuticals's current equity amortized cost?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's current equity amortized cost has grown at a -11.6% compound annual growth rate (CAGR), from $27.51M to $16.8M.